Anti-Ganglioside GD2 Recombinant Antibody (SAA3014) (YP115143)

Name: Anti-Ganglioside GD2 Recombinant Antibody (SAA3014)
Brand: abinScience
SKU: YP115143
Price: 191 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

50ug
100ug
1mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер

YP115143

Описание

Anti-Ganglioside GD2 Recombinant Antibody (SAA3014) (YP115143) is a mouse monoclonal antibody detecting Ganglioside GD2 in ELISA, FCM. Suitable for General.

Highlights

●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.

Реактивность видов

General

Применения

ELISA, FCM

Хозяинский вид

Mouse

Клоональность

Monoclonal

Изотип

IgG2a, kappa

ID клона

SAA3014

Цель

Ganglioside GD2

Уровень эндотоксинов

Please contact with the lab for this information.

Чистота

>95% as determined by SDS-PAGE.

Очистка

Protein A/G purified from cell culture supernatant.

Номер доступа

CAS: 65988-71-8

Форма

Liquid

Буфер хранения

0.01M PBS pH 7.4

Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.

Реконституция

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Информация об использовании продукта

Применение	Разбавление
ELISA	1:2000-1:20000

Устойчивость и хранение

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Фон

Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity.
• Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer., PMID:34596246
• GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214
• Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers., PMID:38593230
• Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma., PMID:39726234
• Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma., PMID:33479234
• Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849
• RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype., PMID:32486168
• Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M⁺ diffuse midline gliomas., PMID:29662203
• Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma., PMID:20879881

Примечание

For research use only

Изображения

Ссылки

Даташит